Doina Ganea

Department of Microbiology and Immunology School of Medicine, Temple University

Research Area

Biography

Doina Ganea has not added Biography.
If you are Doina Ganea and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 200	2011

Other Publications

Article	Year
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino acids\| PubMed ID: 22139413	2011
Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10. Journal of neuroimmunology\| PubMed ID: 12020953	2002
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists\| PubMed ID: 12090463	2002
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia\| PubMed ID: 12112366	2002
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 12223451	2002
Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Experimental hematology\| PubMed ID: 12225791	2002
VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. Journal of neuroimmunology\| PubMed ID: 12446011	2002
Galanin down-regulates microglial tumor necrosis factor-alpha production by a post-transcriptional mechanism. Journal of neuroimmunology\| PubMed ID: 12507772	2003
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. Journal of leukocyte biology\| PubMed ID: 12525573	2003
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochemical and biophysical research communications\| PubMed ID: 12589787	2003
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochemical and biophysical research communications\| PubMed ID: 12604342	2003
Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 12626429	2003
The neuropeptides VIP/PACAP and T cells: inhibitors or activators? Current pharmaceutical design\| PubMed ID: 12678866	2003
PACAP in immunity and inflammation. Annals of the New York Academy of Sciences\| PubMed ID: 12794054	2003
Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 12923064	2003
Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. Journal of leukocyte biology\| PubMed ID: 12960284	2003
Acute down-regulation of antibody production following spinal cord injury: role of systemic catecholamines. Journal of neuropathology and experimental neurology\| PubMed ID: 14503640	2003
Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cellular immunology\| PubMed ID: 14527510	2003
VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. Journal of leukocyte biology\| PubMed ID: 15020654	2004
The significance of vasoactive intestinal peptide in immunomodulation. Pharmacological reviews\| PubMed ID: 15169929	2004
Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 15180965	2004
VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 15231725	2004
A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. The Journal of biological chemistry\| PubMed ID: 15498767	2004
Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 15557192	2004
Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16150720	2005
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. Journal of leukocyte biology\| PubMed ID: 16204628	2005
The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 16301637	2005
Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 16365400	2006
Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood\| PubMed ID: 16397128	2006
Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. European journal of immunology\| PubMed ID: 16402407	2006
Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood\| PubMed ID: 16418327	2006
Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16537513	2006
Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. The American journal of pathology\| PubMed ID: 16565493	2006
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. Annals of the New York Academy of Sciences\| PubMed ID: 16888164	2006
Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation. Annals of the New York Academy of Sciences\| PubMed ID: 16888171	2006
Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis. Annals of the New York Academy of Sciences\| PubMed ID: 16888172	2006
VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Annals of the New York Academy of Sciences\| PubMed ID: 16888178	2006
VIP protects Th2 cells by downregulating granzyme B expression. Annals of the New York Academy of Sciences\| PubMed ID: 16888222	2006
A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation. Peptides\| PubMed ID: 17462790	2007
The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 17548652	2007
Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis and rheumatism\| PubMed ID: 17665454	2007
Neuropeptides: active participants in regulation of immune responses in the CNS and periphery. Brain, behavior, and immunity\| PubMed ID: 17706916	2008
PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood\| PubMed ID: 17925490	2008
A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology\| PubMed ID: 18040812	2006
In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 18566439	2008
Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain, behavior, and immunity\| PubMed ID: 18598752	2008
Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 18802056	2008
Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury. Clinical neurosurgery\| PubMed ID: 19248685	2008
Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology\| PubMed ID: 19255856	2009
CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvascular research\| PubMed ID: 19332079	2009
Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation. Blood\| PubMed ID: 19531658	2009
Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 20068554	2010
Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family. Lipids in health and disease\| PubMed ID: 20122166	2010
IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 20190134	2010
The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse ... Clinical neurosurgery\| PubMed ID: 20214038	2009
Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Current opinion in pharmacology\| PubMed ID: 20399708	2010
Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain, behavior, and immunity\| PubMed ID: 20854895	2011
Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation. Clinical lipidology\| PubMed ID: 21804863	2011
Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation. The Journal of biological chemistry\| PubMed ID: 21940623	2011
Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. Journal of neurotrauma\| PubMed ID: 21970496	2011